Background
Pic

Bringing surgery to the 21st century

The concept


Olfactomics is a Finnish company that develops novel technology for surgical tissue assessment.

We focus on improving surgical management of breast cancer where identification of cancerous tissue during surgery is paramount. By enabling realtime tissue analysis allow the surgeon to make informed decisions and remove the whole tumor in one operation while sparing as much healthy tissue as possible.

Our goal is to save 100 000 women from unnecessary reoperations and one billion dollars in healthcare costs.

Parallax image 1

The technology

The heart of Olfactomics' technology is a differential ion mobility spectrometry (DMS) sensor. In contrast to traditional mass spectrometry, DMS does not require vacuum and is significantly more robust and economical to operate.

The system consists of sample preparation, sensor and data analytics. The principle is very similar to the way we humans use our olfaction to our advantage:

eNose principle
  • Volatile compounds are introduced into an apparatus that optimizes the temperature, moisture and consentration of the sample.
  • The compounds interact with the olfactory cells or an artificial sensor, creating electric signals.
  • Electric signals are relayed to brains or a computer that filter and analyze the signals.
  • Signals are associated with previous knowledge. A conclusion is made.

The foundation of our company is science. In references you will find selected publications from our team. Several papers on the Olfactomics' technology are currently under review.

Parallax image 1

The Team

Our team is characterized by a close connection between the clinic, the university, engineering and business professionals.

The practising surgeons of our team constantly spar ideas with our engineering team, resulting in agile, clinically oriented development.

We work closely with medical device manufacturers, sensor companies and the software industry to create maximum accuracy, reliability and value.

News

Olfactomics joins prestigious Medtech accelerator

19.6.2019

Olfactomics is honored to join Medtech Innovator, a prestigious medical device startup accelerator founded by medtech giants and venture capitalists.

Read more: Press release

Olfactomics acguires SME2 grant from European Union Horizon 2020 program

30.1.2019

Olfactomics continues strong performance in European Union's Horizon 2020 program, acguiring SME2 grant to continue the development of novel tool for surgical margin assessment.

Read more: Press release

Olfactomics acguires SME1 grant from European Union Horizon 2020 program

29.6.2018

Olfactomics received a grant from European Union's SME Horizon 2020 program. Only 3% of the applicants are funded.

Read more: Press release (in Finnish)

An article on Olfactomics technology in discrimination of animal tissues was just published

24.4.2018

A research paper by Anton Kontunen describing differential mobility spectrometry was published on highly regarded Annals of Biomedical Engineering!

Read more: Annals of Biomedical Engineering

Niku Oksala tells about Olfactomics technology on Helsingin sanomat

3.1.2018

Olfactomics co-founder Niku Oksala was interviewed by Helsingin sanomat on his life as a surgeon, academic, inventor and entrepeneur. Olfactomics tissue detection technology plays a major role.

Read more: Helsingin sanomat

Olfactomics results presented at The Operative days of the Finnish Society of Surgery

16.11.2017

An oral presentation on the results acquired with Olfactomics technology in breast cancer were presented at The Operative days of the Finnish Society of Surgery.

Read more: Finnish Society of Surgery

Olfactomics joins the SPARK Finland

29.9.2017

Olfactomics is now part of Stanford-bred medtech incubator.

Read more: SPARK Finland - New SPARKees join the program

Electronic nose `smells` cancer

22.9.2017

MSc Anton Kontunen explains how surgical smoke can tell whether the tissue is cancerous or not.

Read more: Interface science magazine - Electronic nose `smells` cancer

Sniffing out Prostate Cancer from Dogs to the eNose

7.1.2015

"It is always humbling to see how much you can miss in trying to keep up with medicine's developments, even in an incredibly narrow area like prostate cancer."

Read the whole article from Asco Connection

Parallax image 2

References

Scientific results are the basis of our operation.

Tissue Identification in a Porcine Model by Differential Ion Mobility Spectrometry Analysis of Surgical Smoke

Kontunen A, Karjalainen M, Lekkala J, Roine A, Oksala N.
Ann Biomed Eng. First Online: 24 April 2018. doi: https://doi.org/10.1007/s10439-018-2035-5.
https://link.springer.com/article/10.1007%2Fs10439-018-2035-5


Electronic Nose in the Detection of Wound Infection Bacteria from Bacterial Cultures: A Proof-of-Principle Study

Saviauk T, Kiiski JP, Nieminen MK, Tamminen NN, Roine AN, Kumpulainen PS, Hokkinen LJ, Karjalainen MT, Vuento RE, Aittoniemi JJ, Lehtimäki TJ, Oksala NK.
Eur Surg Res. 2018 Jan 10;59(1-2):1-11. doi: 10.1159/000485461.
https://www.ncbi.nlm.nih.gov/pubmed/29320769


Rapid and accurate detection of urinary pathogens by mobile IMS-based electronic nose: a proof-of-principle study

Roine A, Saviauk T, Kumpulainen P, Karjalainen M, Tuokko A, Aittoniemi J, Vuento R, Lekkala J, Lehtimäki T, Tammela TL, Oksala NK.
PLoS One. 2014 Dec 19;9(12):e114279. doi: 10.1371/journal.pone.0114279.
http://www.ncbi.nlm.nih.gov/pubmed/25526592


Detection of prostate cancer by an electronic nose: a proof of principle study

Roine A, Veskimäe E, Tuokko A, Kumpulainen P, Koskimäki J, Keinänen TA, Häkkinen MR, Vepsäläinen J, Paavonen T, Lekkala J, Lehtimäki T, Tammela TL, Oksala NK.
J Urol. 2014 Jul;192(1):230-4. doi: 10.1016/j.juro.2014.01.113.
http://www.ncbi.nlm.nih.gov/pubmed/24582536


Detection of smell print differences between nonmalignant and malignant prostate cells with an electronic nose

Roine A, Tolvanen M, Sipiläinen M, Kumpulainen P, Helenius MA, Lehtimäki T, Vepsäläinen J, Keinänen TA, Häkkinen MR, Koskimäki J, Veskimäe E, Tuokko A, Visakorpi T, Tammela TL, Sioris T, Paavonen T, Lekkala J, Helle H, Oksala NK.
Future Oncol. 2012 Sep;8(9):1157-65. doi: 10.2217/fon.12.93.
http://www.ncbi.nlm.nih.gov/pubmed/23030490

In cooperation with

We work closely with the academic and industrial sectors.

Contact us

Want to hear more about us? Are You the missing link in our growing team of professionals? Don't hesitate to contact us! Please fill out the form and we will be in touch.


 info@olfactomics.fi   
 +358 408410698   
 Korkeakoulunkatu 7, Kampusareena, FI-33720 Tampere, FINLAND